Nuvectis, Haisco ink up to $1.4B deal for two late-stage programs

Nuvectis In-licenses Two Late-Stage Programs from Haisco in $1.4B Deal

Nuvectis has in-licensed exclusive worldwide rights (excluding China, India, and specific Southeast Asia for NXP100) to two late-stage assets, NXP100 and NXP200, from China's Haisco Pharmaceutical. The deal includes $40 million in upfront and near-term payments, with Haisco eligible for up to $1.42 billion in biobucks and tiered royalties. NXP100, an oral complement Factor B inhibitor, is under regulatory review in China for paroxysmal nocturnal hemoglobinuria (PNH) and in Phase 3 for IgA nephropathy. NXP200, an oral paradox-breaker BRAF inhibitor, is in a Phase 1b study for BRAF-mutated solid tumors. This agreement propels Nuvectis into late-stage development.

• Strategic Licensing Agreement Details: Nuvectis has secured exclusive global rights, excluding specific Asian territories for NXP100, to Haisco's NXP100 and NXP200. The financial terms involve $40 million in upfront and near-term payments, with potential milestone payments reaching $1.42 billion and additional tiered royalties. This deal significantly advances Nuvectis's pipeline into late-stage clinical development, marking a pivotal expansion beyond its previous early-stage focus.
• NXP100's Advanced Development and Market Potential: NXP100, an oral complement Factor B inhibitor, is a key asset with multiple advanced programs. It is currently undergoing two regulatory reviews for approval in China for paroxysmal nocturnal hemoglobinuria (PNH), a rare genetic blood disorder. Additionally, it is in an ongoing Phase 3 trial for immunoglobulin A nephropathy and has been evaluated in a mid-stage study for lupus nephritis. Nuvectis anticipates NXP100 could offer a convenience advantage as a once-daily oral treatment, particularly in the PNH market projected to exceed $5 billion by 2026.
• NXP200's Novel Mechanism and Oncology Focus: The second asset, NXP200, is an oral paradox-breaker BRAF inhibitor, representing a next-generation approach to targeting BRAF mutations. This inhibitor is designed for greater selectivity, aiming to avoid the activation of cell pathways triggered by older BRAF inhibitors. NXP200 is currently being investigated in a Phase 1b study in China for various BRAF V600X-mutated and Class II/III non-V600-mutated solid tumor malignancies, including colorectal cancer, melanoma, and non-small-cell lung cancer, addressing significant unmet needs in oncology.

Positioning NXP100 Against Current PNH Therapies

The therapeutic landscape for PNH has undergone a fundamental shift with the emergence of complement-targeting agents that significantly outperform historical standard-of-care approaches. Eculizumab, the established C5 inhibitor and current standard of care, demonstrated a 3-year survival estimate of 97.6% in long-term data, with a median 86.9% reduction in LDH at 36 months, an 81.8% decrease in thrombotic events, and transfusion independence achieved in 90.0% of patients — with no evidence of cumulative toxicity. Its next-generation successor, ravulizumab, offers an equivalent efficacy and safety profile but with extended dosing intervals of every 4–8 weeks based on patient weight, meaningfully reducing infusion burden, healthcare utilization, and associated quality-of-life costs. In contrast, earlier treatment paradigms — antithymocyte globulin (ATG) and bone marrow transplantation (BMT) — carried substantially worse long-term outcomes, with ATG-treated patients showing survival rates declining from 63% at 7 years to 43% at 11 years, and BMT associated with high rates of graft-versus-host disease and only 32% survival at 7 years.

Investigational and recently approved proximal complement inhibitors now represent a more comprehensive approach to hemolysis control, addressing the limitations of distal C5 blockade. Pegcetacoplan, the first proximal C3 inhibitor, demonstrated rapid and sustained hematologic benefit in a real-world Spanish cohort of 32 patients: median hemoglobin increased by 2.65 g/dL within 4 weeks, transfusion requirements fell from 62.5% to 15.6% of patients, and breakthrough hemolysis decreased from 34.4% to 9.4% at 6 months, with no thrombotic events and only mild adverse events in 34% of patients. Iptacopan, an oral Factor B inhibitor, similarly showed significant hemoglobin improvement (mean difference +12.98 g/L; p < 0.0001) and LDH reduction (mean difference −83.55 IU/L; p < 0.0001) across a systematic review of 197 patients, with a favorable safety profile and only one patient discontinuing due to adverse effects. Danicopan, an oral Factor D inhibitor, reduced LDH from 5.7× to 1.8× the upper limit of normal by day 28 in a small cohort, further supporting the proximal pathway as a viable therapeutic target.

Crovalimab, a next-generation anti-C5 monoclonal antibody, achieved a hemolysis control rate of 86% (95% CI: 77%–94%) and transfusion avoidance in 77% of patients across a 2026 meta-analysis of 275 patients, with serious adverse events in 15% — a profile broadly consistent with eculizumab-class agents. Notably, biosimilar eculizumab (Elizaria®) maintained stable LDH, hemoglobin, and PNH clone parameters through 104 weeks with adverse reactions in only 6.6% of patients, suggesting equivalent durability to the reference product. Across the evolving treatment spectrum, oral agents such as iptacopan and danicopan introduce a significant practical advantage over intravenous regimens, while proximal complement inhibitors offer broader hemolysis control — including extravascular hemolysis not addressed by C5-targeted therapies — positioning them as compelling candidates for patients with suboptimal responses to current standard of care.

The Evolving PNH Landscape and Nuvectis' Strategic Entry

Over the past five years, the PNH treatment landscape has undergone a fundamental shift away from exclusive reliance on anti-C5 monoclonal antibodies toward a broader, mechanistically diverse therapeutic armamentarium. Eculizumab, long the standard of care, has demonstrated sustained effectiveness in long-term post-marketing surveillance — including a Japanese registry study of 632 patients with a median treatment duration of 3.6 years — but its limitations have become increasingly well-defined. Real-world data show that 29.4% of eculizumab-treated patients experience breakthrough hemolysis and require higher-than-label dosing in over a third of cases, with total annual per-patient healthcare costs exceeding $700,000. Ravulizumab, a long-acting C5 inhibitor administered every eight weeks, has addressed some of the treatment-burden concerns associated with eculizumab's biweekly infusion schedule. Extension data from Studies 301 and 302 confirm transfusion independence in 86.8% of eculizumab-experienced patients and 76.5% of C5 inhibitor-naïve patients, with major adverse vascular event rates of 0.4 per 100 person-years and a lower risk of breakthrough intravascular hemolysis relative to eculizumab. Despite these advances, 44.1% of patients treated with C5 inhibitors still experience at least one complication, underscoring persistent unmet need.

Proximal complement inhibitors have emerged as the most clinically significant development in this period, targeting upstream pathway components to address both intravascular and extravascular hemolysis — the latter being inadequately controlled by C5 inhibitors. Iptacopan, a first-in-class oral factor B inhibitor, demonstrated compelling efficacy in the pivotal Phase 3 APPLY-PNH and APPOINT-PNH trials. At week 48, 86% of anti-C5-experienced patients in APPLY-PNH achieved a hemoglobin increase of ≥2 g/dL, and 68% reached hemoglobin concentrations ≥12 g/dL; results were even more pronounced in complement inhibitor-naïve patients in APPOINT-PNH (97% and 79%, respectively). Clinical breakthrough hemolysis occurred in only 7% and 5% of iptacopan-treated patients across the two trials, with no treatment discontinuations due to adverse events. Pegcetacoplan, a C3/C3b inhibitor administered subcutaneously, has similarly shown robust real-world performance in patients with extravascular hemolysis on prior C5 inhibition — achieving a median hemoglobin of 12.0 g/dL at 12 months, reducing breakthrough hemolysis from 34.4% to 9.4% at six months, and improving FACIT-Fatigue scores from a mean of 28.4 at baseline to 38.6 at three months. Danicopan, an oral factor D inhibitor used as an add-on to C5 therapy, demonstrated a least-squares mean hemoglobin improvement of 2.94 g/dL versus 0.50 g/dL for placebo in the ALPHA trial at week 12, though cost-effectiveness analyses have found its addition to ravulizumab at current annual pricing ($12,300–$13,100) to be economically unfavorable compared to ravulizumab alone.

The competitive evolution of the PNH landscape is further shaped by cost-effectiveness data and expanding access considerations. Pharmacoeconomic analyses position pegcetacoplan as dominant over C5 inhibitors and iptacopan in several modelling frameworks, while iptacopan monotherapy has been shown to accrue 12.6 quality-adjusted life-years at $9.52 million versus 10.8 QALYs at $13.5 million for standard of care — remaining cost-saving across 100% of Monte Carlo sensitivity iterations. The introduction of eculizumab biosimilars, such as Elizaria®, further expands the access landscape; a 104-week study in 30 PNH patients confirmed stable LDH, hemoglobin, reticulocyte, and PNH clone levels relative to baseline, with an adverse reaction rate of only 6.6% and no antidrug antibody signals. Collectively, published trial data from this period depict a landscape in transition: one where oral, proximal-acting agents are increasingly challenging intravenous C5 inhibition as the preferred therapeutic backbone, and where both clinical outcomes and economic value are driving treatment sequencing decisions at the strategic level.

Nuvectis's Bold Leap into Late-Stage Complement and Oncology

This in-licensing agreement marks a pivotal moment for Nuvectis, catapulting the company into late-stage clinical development across two distinct, high-value therapeutic areas. The acquisition of NXP100 and NXP200 represents a calculated move to diversify and accelerate their pipeline, leveraging established mechanisms of action with potentially differentiated profiles.

NXP100, an oral complement Factor B inhibitor, is poised to enter markets for paroxysmal nocturnal hemoglobinuria (PNH) and IgA nephropathy (IgAN). In PNH, Factor B inhibition offers a mechanism to address both intravascular and extravascular hemolysis, potentially improving patient quality of life and transfusion independence beyond C5 inhibitors. For IgAN, where complement activation is a key driver, Factor B inhibition has demonstrated significant reductions in proteinuria and a slower decline in kidney function, offering a novel, targeted approach in a disease with high unmet need. However, NXP100 will need to carve out its niche in a competitive landscape already populated by multiple complement inhibitors for PNH and emerging therapies for IgAN, including other Factor B inhibitors.

The oral paradox-breaker BRAF inhibitor, NXP200, targets BRAF-mutated solid tumors, a landscape where BRAF inhibitors are standard but resistance remains a significant challenge. The 'paradox-breaker' designation suggests a potential to overcome some of the known resistance mechanisms, such as secondary RAS mutations or hyperactivated bypass signaling, which limit the long-term efficacy of current BRAF/MEK combinations. Yet, NXP200, currently in Phase 1b, faces the formidable task of demonstrating superior outcomes or a more favorable tolerability profile compared to established BRAF/MEK inhibitor combinations, which have already set high benchmarks for progression-free and overall survival in melanoma. The persistent issue of acquired resistance for all BRAF inhibitors means NXP200 will need to show how its unique mechanism translates into sustained clinical benefit. Nuvectis's success will hinge on robust clinical data and a well-defined market strategy to differentiate these assets in their respective competitive therapeutic spaces.